Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

NCT: NCT07224880 · COMPLETED

NCT IDNCT07224880
StatusCOMPLETED
Start Date2025-10-14
Completion2026-08-21
SponsorCytrellis Biosystems, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Frequently Asked Questions

What is Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists?

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists is a clinical trial registered under NCT07224880. Current status: COMPLETED.

What is the status of NCT07224880?

The current status of NCT07224880 (Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists) is: COMPLETED.

When did Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists start?

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists started on 2025-10-14.

Related Devices

K252752ellacor System with Micro-Coring TechnologyCytrellis Biosystems, Inc. K202517Cytrellis Dermal Micro-Coring SystemCytrellis Biosystems, Inc. K162106Micro-current Wrinkle Reduction Facial service, model EP-400Li-Tek Electronic Technology Corporation

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑